Non-Current Liabilities
Long-Term Debt
Pfizer Long-Term Debt increased by 7.4% to $61.64B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 7.4%, from $57.41B to $61.64B. Over 5 years (FY 2020 to FY 2025), Long-Term Debt shows an upward trend with a 10.7% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ3 2015
Last reportedQ4 2025
How to read this metric
An increase indicates higher financial leverage, which can amplify returns on equity but also increases interest expense and financial risk.
Detailed definition
Loans and financial obligations with a maturity period exceeding one year, typically consisting of corporate bonds and n...
Peer comparison
Capital-intensive firms or those with aggressive share buyback programs often carry higher long-term debt than asset-light competitors.
Metric ID:
long_term_debtHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $35.35B | $36.25B | $36.20B | $35.66B | $34.29B | $32.63B | $32.88B | $31.70B | $61.36B | $61.05B | $61.54B | $61.31B | $57.51B | $58.00B | $57.41B | $57.64B | $57.50B | $57.41B | $61.64B |
| QoQ Change | — | +2.5% | -0.2% | -1.5% | -3.8% | -4.9% | +0.8% | -3.6% | +93.5% | -0.5% | +0.8% | -0.4% | -6.2% | +0.9% | -1.0% | +0.4% | -0.2% | -0.2% | +7.4% |
| YoY Change | — | — | — | — | -3.0% | -10.0% | -9.1% | -11.1% | +78.9% | +87.1% | +87.1% | +93.4% | -6.3% | -5.0% | -6.7% | -6.0% | -0.0% | -1.0% | +7.4% |
Range$31.70B – $61.64B
CAGR+13.1%
Avg YoY Growth+19.7%
Median YoY Growth-3.0%
Long-Term Debt at Other Companies
Frequently Asked Questions
- What is Pfizer's long-term debt?
- Pfizer (PFE) reported long-term debt of $61.64B in Q4 2025.
- How has Pfizer's long-term debt changed year-over-year?
- Pfizer's long-term debt increased by 7.4% year-over-year, from $57.41B to $61.64B.
- What is the long-term trend for Pfizer's long-term debt?
- Over 5 years (2020 to 2025), Pfizer's long-term debt has grown at a 10.7% compound annual growth rate (CAGR), from $37.13B to $61.64B.
- What does long-term debt mean?
- Money the company has borrowed that doesn't need to be paid back for at least a year.